Epizyme Inc (EPZM) : Ecor1 Capital reduced its stake in Epizyme Inc by 52.78% during the most recent quarter end. The investment management company now holds a total of 755,046 shares of Epizyme Inc which is valued at $6,289,533 after selling 843,854 shares in Epizyme Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Epizyme Inc makes up approximately 2.71% of Ecor1 Capital’s portfolio.
Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in EPZM in the latest quarter, The investment management firm added 7,000 additional shares and now holds a total of 19,400 shares of Epizyme Inc which is valued at $161,602. Group One Trading sold out all of its stake in EPZM during the most recent quarter. The investment firm sold 2,700 shares of EPZM which is valued $22,491.Tfs Capital boosted its stake in EPZM in the latest quarter, The investment management firm added 559 additional shares and now holds a total of 139,448 shares of Epizyme Inc which is valued at $1,161,602. Epizyme Inc makes up approx 0.20% of Tfs Capital’s portfolio.Teacher Retirement System Of Texas boosted its stake in EPZM in the latest quarter, The investment management firm added 653 additional shares and now holds a total of 5,398 shares of Epizyme Inc which is valued at $48,852. Woodstock Corp added EPZM to its portfolio by purchasing 27,534 company shares during the most recent quarter which is valued at $278,093. Epizyme Inc makes up approx 0.06% of Woodstock Corp’s portfolio.
Epizyme Inc (EPZM) witnessed a volatile trading activity on Thursday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $7.23 and reached the intraday high at $7.54. The bulls started the profit booking and pushed the shares to intraday low of $7.2. The trading session was marked by a volume range of 2,43,154 shares exchanging hands. The 52-week high of the shares is $21.16 and the 52-week low is $7.14. The market cap of the company stands at $424 M and there are 5,79,56,977 shares in public circulation.
Epizyme Inc. is a clinical-stage biopharmaceutical company that discovers develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases or HMTs. The Company’s lead product candidate EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling and Phase I MLL-r pediatric patient trial enrolling.